Stockreport

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial [Yahoo! Finance]

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE's LB-100 to GSK's programmed death receptor-1 (PD-1)-blocking mon [Read more]